Pathology: mNSCLC - L2 - all population; mNSCLC - L2 - EGFR mutant; mNSCLC - L2 - PDL1 negative; mNSCLC - L2 - PDL1 positive; non squamous - mNSCLC - L2 - all population; squamous - mNSCLC - L2 - all population;
mNSCLC - L2 - all population | mNSCLC - L2 - EGFR mutant | mNSCLC - L2 - PDL1 negative | mNSCLC - L2 - PDL1 positive | non squamous - mNSCLC - L2 - all population | squamous - mNSCLC - L2 - all population | ||||||||||||
OAK (all population), 2016 | POPLAR, 2016 | JAVELIN Lung 200 (all population), 2018 | CheckMate 078, 2019 | RATIONALE 303, 0 | CAURAL (EXPLORATORY), 2019 | ARCTIC (DT ; study B ; PDL1<25%), 2020 | OAK (PDL1 TC 1/2/3), 2016 | JAVELIN Lung 200 (PDL1 >1%), 2018 | ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 | KEYNOTE-010 (P:10 mg/kg ; PDL1>50%), 2016 | KEYNOTE-010 (P:10 mg/kg), 2016 | KEYNOTE-010 (P: 2mg/kg ; PDL1>50%), 2016 | KEYNOTE-010 (P: 2mg/kg), 2016 | CheckMate 057, 2015 | CheckMate 017, 2015 | ||
atezolizumab alone | 3 | T1 | T1 | T1 | |||||||||||||
nivolumab alone | 3 | T1 | T1 | T1 | |||||||||||||
avelumab alone | 2 | T1 | T1 | ||||||||||||||
pembrolizumab (10mg/kg) | 2 | T1 | T1 | ||||||||||||||
pembrolizumab (2mg/kg) | 2 | T1 | T1 | ||||||||||||||
Tislelizumab | 1 | T1 | |||||||||||||||
durvalumab plus tremelimumab | 1 | T1 | |||||||||||||||
durvalumab alone | 1 | T1 | |||||||||||||||
durvalumab plus osimertinib | 1 | T1 | |||||||||||||||
Standard of Care (SoC) | 0 | T0 | T0 | ||||||||||||||
osimertinib | 0 | T0 | |||||||||||||||
docetaxel | 0 | T0 | T0 | T0 | T0 | T0 | T0 | T0 | T0 | T0 | T0 | T0 | T0 | T0 |